LYSODREN
What it isAdrenolytic agent destroying adrenocortical cells; adrenocortical carcinoma and Cushing syndrome.
Why this oneIt is the only drug that is directly cytotoxic to the adrenal cortex.
What limits itIt causes adrenal insufficiency by design, so glucocorticoid replacement at higher-than-usual doses is mandatory. Neurotoxicity; it induces CYP3A4.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Adrenocortical carcinoma | Adult | 2000–6000 mg/day in 3–4 divided doses | Plasma 14–20 mg/L |
Renal Not recommended in severe impairment; in mild–moderate, monitor plasma levels frequently and adjust.
Hepatic Not recommended in severe impairment; in mild–moderate, monitor plasma levels frequently and adjust.
Titrate to plasma level 14–20 mg/L; neurotoxicity more likely >20 mg/L; levels may persist for weeks after stopping due to adipose accumulation.
Pregnancy Can cause fetal harm; preterm births and early pregnancy loss reported.
Lactation Excreted in human milk; do not breastfeed during treatment and while plasma levels remain detectable.
⚠ BOXED WARNING
Cost, est. cash$5,000–$30,000+/month or cycle
Generic entryNo US generic
Legacy pregnancy categoryD
Defining liabilityMyelosuppression and agent-specific hepatic, cardiac, pulmonary, neurologic or reproductive toxicity require oncology monitoring.
